- Home
- BYRN vs DNA Comparison
BYRN vs DNA Comparison
Compare BYRN & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYRN
- DNA
- Stock Information
- Founded
- BYRN 2005
- DNA 2008
- Country
- BYRN United States
- DNA United States
- Employees
- BYRN N/A
- DNA N/A
- Industry
- BYRN Industrial Machinery/Components
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BYRN Miscellaneous
- DNA Health Care
- Exchange
- BYRN Nasdaq
- DNA Nasdaq
- Market Cap
- BYRN 530.6M
- DNA 529.8M
- IPO Year
- BYRN N/A
- DNA N/A
- Fundamental
- Price
- BYRN $17.24
- DNA $7.87
- Analyst Decision
- BYRN Strong Buy
- DNA Strong Sell
- Analyst Count
- BYRN 2
- DNA 1
- Target Price
- BYRN $41.50
- DNA $9.00
- AVG Volume (30 Days)
- BYRN 384.5K
- DNA 1.3M
- Earning Date
- BYRN 10-09-2025
- DNA 11-06-2025
- Dividend Yield
- BYRN N/A
- DNA N/A
- EPS Growth
- BYRN 543.53
- DNA N/A
- EPS
- BYRN 0.66
- DNA N/A
- Revenue
- BYRN $110,853,000.00
- DNA $180,606,000.00
- Revenue This Year
- BYRN $39.82
- DNA N/A
- Revenue Next Year
- BYRN $20.48
- DNA $14.41
- P/E Ratio
- BYRN $26.25
- DNA N/A
- Revenue Growth
- BYRN 50.99
- DNA N/A
- 52 Week Low
- BYRN $13.68
- DNA $5.00
- 52 Week High
- BYRN $34.78
- DNA $17.58
- Technical
- Relative Strength Index (RSI)
- BYRN 34.81
- DNA 27.86
- Support Level
- BYRN $16.76
- DNA $7.65
- Resistance Level
- BYRN $18.95
- DNA $8.27
- Average True Range (ATR)
- BYRN 1.00
- DNA 0.71
- MACD
- BYRN -0.17
- DNA -0.36
- Stochastic Oscillator
- BYRN 10.82
- DNA 8.44
About BYRN Byrna Technologies Inc.
Byrna Technologies Inc is a designer, manufacturer, retailer, and distributor of technological solutions for security situations that do not require the use of lethal force. The company generates its revenue from the United States, South Africa, Europe, South America, Asia, and Canada.
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.